Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $13.4 million.

  • Heron Therapeutics' Cash from Financing Activities rose 9535000.0% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year increase of 194343.58%. This contributed to the annual value of $940000.0 for FY2024, which is 9826.27% down from last year.
  • Per Heron Therapeutics' latest filing, its Cash from Financing Activities stood at $13.4 million for Q3 2025, which was up 9535000.0% from $781000.0 recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Cash from Financing Activities ranged from a high of $154.7 million in Q2 2021 and a low of -$637000.0 during Q1 2022
  • Its 5-year average for Cash from Financing Activities is $15.8 million, with a median of $423000.0 in 2024.
  • Within the past 5 years, the most significant YoY rise in Heron Therapeutics' Cash from Financing Activities was 10565211.27% (2022), while the steepest drop was 17214.04% (2022).
  • Over the past 5 years, Heron Therapeutics' Cash from Financing Activities (Quarter) stood at $487000.0 in 2021, then decreased by 9.86% to $439000.0 in 2022, then plummeted by 54.67% to $199000.0 in 2023, then surged by 112.56% to $423000.0 in 2024, then soared by 3059.1% to $13.4 million in 2025.
  • Its Cash from Financing Activities was $13.4 million in Q3 2025, compared to $781000.0 in Q2 2025 and $64000.0 in Q1 2025.